Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Knuth

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Nature Communications|March 7, 2013
Aldara activates TLR7-independent immune defenceAnne Walter, Matthias Schäfer, Virginia Cecconi, et al.
International Journal of Cancer|March 3, 2007
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancerInka Seil, Claudia Frei, Holger Sültmann, et al.
Cancer Research|April 17, 2008
New derivatives of vitamin B12 show preferential targeting of tumorsRobert Waibel, Hansjörg Treichler, Niklaus G Schaefer, et al.
Cancer Immunity|October 20, 2007
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancerArmin Bender, Julia Karbach, Antje Neumann, et al.
Oncology|March 3, 2021
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center StudyHeike Pietge, Patricia Sánchez-Velázquez, Dilara Akhoundova, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2002
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patientsSacha Gnjatic, Elke Jäger, Weisan Chen, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2006
Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patientsAlfred Zippelius, Asma Gati, Tammo Bartnick, et al.
Arthritis and Rheumatism|February 16, 2010
Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblastsCaroline Ospelt, Joachim C Mertens, Astrid Jüngel, et al.
Swiss Medical Weekly|June 2, 2011
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experiencePanagiotis Samaras, Marcel Blickenstorfer, Sarah R Haile, et al.
Annals of Hematology|August 14, 2010
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastimPanagiotis Samaras, Marcel Blickenstorfer, Raffaele Daniele Siciliano, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Nature Communications|March 7, 2013
Aldara activates TLR7-independent immune defenceAnne Walter, Matthias Schäfer, Virginia Cecconi, et al.
International Journal of Cancer|March 3, 2007
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancerInka Seil, Claudia Frei, Holger Sültmann, et al.
Cancer Research|April 17, 2008
New derivatives of vitamin B12 show preferential targeting of tumorsRobert Waibel, Hansjörg Treichler, Niklaus G Schaefer, et al.
Cancer Immunity|October 20, 2007
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancerArmin Bender, Julia Karbach, Antje Neumann, et al.
Oncology|March 3, 2021
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center StudyHeike Pietge, Patricia Sánchez-Velázquez, Dilara Akhoundova, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2002
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patientsSacha Gnjatic, Elke Jäger, Weisan Chen, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2006
Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patientsAlfred Zippelius, Asma Gati, Tammo Bartnick, et al.
Arthritis and Rheumatism|February 16, 2010
Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblastsCaroline Ospelt, Joachim C Mertens, Astrid Jüngel, et al.
Swiss Medical Weekly|June 2, 2011
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experiencePanagiotis Samaras, Marcel Blickenstorfer, Sarah R Haile, et al.
Annals of Hematology|August 14, 2010
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastimPanagiotis Samaras, Marcel Blickenstorfer, Raffaele Daniele Siciliano, et al.
Pageof 13